[DEBUG-WINDOW 처리영역 보기]
즐겨찾기  |  뉴스레터  |  오늘의 정보 회원가입   로그인
BRIC홈 한국을 빛내는 사람들
ACROBIOSYSTEMS
배너광고안내
이전
다음
스폰서배너광고 안내  배너1 배너2 배너3 배너4
전체보기 한빛사논문 추천논문 상위피인용논문 인터뷰 그이후 한빛사통계
안명주 (Myung-Ju Ahn) 저자 이메일 보기
성균관대학교 의과대학
CV PDF 816 KB
관련인물
16
Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial
J. Thorac. Oncol., Available online 15 February 2022 | https://doi.org/10.1016/j.jtho.2022.01.012
( 2022-02 ) Medicine, Cancer Biology/Oncology | 
한빛사논문
A Phase 1/2 Study of Lazertinib 240 mg in Patients with Advanced EGFR T790M-Positive Non-Small Cell Lung Cancer After Prior EGFR Tyrosine Kinase Inhibitors
J. Thorac. Oncol., Available online 24 December 2021 | https://doi.org/10.1016/j.jtho.2021.11.025
( 2021-12 ) Medicine, Cancer Biology/Oncology | 
한빛사논문
Brain metastases in patients with oncogenic-driven non-small cell lung cancer: Pros and cons for early radiotherapy
Cancer Treat. Rev., Available online 11 September 2021, 102291 | https://doi.org/10.1016/j.ctrv.2021.102291
( 2021-09 ) Medicine, Cancer Biology/Oncology | 
한빛사논문
Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell Lung Cancer
J. Thorac. Oncol., Volume 4, Issue 7, July 2009, Pages 809-815 | https://doi.org/10.1097/JTO.0b013e3181a94af4
( 2009-07 ) | 
상위피인용논문
Osimertinib improves overall survival in EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastases regardless of T790M mutational status
J. Thorac. Oncol., Volume 15, Issue 11, November 2020, Pages 1758-1766 | https://doi.org/10.1016/j.jtho.2020.06.018
( 2020-11 ) Cancer Biology/Oncology, Medicine | 
한빛사논문
A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy
Ann. Oncol., Available online 5 July 2020 | https://doi.org/10.1016/j.annonc.2020.06.017
( 2020-07 ) Cancer Biology/Oncology | 
한빛사논문
136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial
J. Thorac. Oncol., Volume 11, Issue 4, Supplement, April 2016, Page S115 | https://doi.org/10.1016/S1556-0864(16)30246-5
( 2016-04 ) | 
상위피인용논문
Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma
Nat. Commun., Published: 08 May 2020 11, Article number: 2285 (2020) | https://doi.org/10.1038/s41467-020-16164-1
( 2020-05 ) Bioinformatics, Cancer Biology/Oncology, Genomics | 
한빛사논문
Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study
J. Clin. Oncol., Published online : December 06, 2019 | DOI: 10.1200/JCO.19.00457
( 2019-12 ) Cancer Biology/Oncology | 
한빛사논문
  
Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)
J. Clin. Oncol., Published online : December 11, 2019 | DOI: 10.1200/JCO.19.00931
( 2019-12 ) Cancer Biology/Oncology | 
한빛사논문
처음 이전  1 02  다음 끝
한빛사 안내
한빛사 운영안내
선정저널 목록
최근 3년간 3회 이상 등록 연구자
한빛사논문 결산자료
한빛사 통계
국내 바이오분야 연구성과 Top5
한빛사논문 등록하기 >
연구자정보업데이트 신청하기
최신댓글
Anderson Tan(Cell Death Differ.) 댓글 1
배성호(Gut) 댓글 1
신재우(J. Allergy Clin. Immunol.) 댓글 1
부성호(Cell Reports) 댓글 1
고준영(J. Hepatol.) 댓글 1
이다빈(Redox Biol.) 댓글 1
한종희(Cell Reports) 댓글 1
박홍범(Biochim. Biophys. Acta-Rev. Cancer) 댓글 4
이지현(Cell Stem Cell) 댓글 2
이성민(Blood) 댓글 1
위로가기
한빛사 홈  |  한빛사FAQ
 |  BRIC소개  |  이용안내  |  이용약관  |  개인정보처리방침  |  이메일무단수집거부
Copyright © BRIC. All rights reserved.  |  문의
트위터 트위터    페이스북 페이스북   유튜브 유튜브    RSS서비스 RSS
써모피셔사이언티픽 광고